China China’s National Reimbursement Drug List (NRDL) is the catalogue of medications covered under the country’s public health insurance system. The NRDL aims to enhance healthcare accessibility by subsidizing essential and innovative drugs, thereby reducing out-of-pocket expenses for patients. This 2023 edition of the list, released on December 13th 2023 and…
China DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021: from 34 new chemical drugs and 19 biological products in 2019 to 37 new chemical drugs and 24 biological products…
China Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s reimbursement list in 2021; the former GSK scientist pleading guilty to stealing trade secrets for Chinese pharma; and BioNTech’s continuing…
China The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and the significant price cuts that have been agreed. Also included are the World Health Organization (WHO)’s plea to Chinese COVID-19…
See our Cookie Privacy Policy Here
